Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant
Open Access
- 6 May 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (7) , 993-1003
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare extranodal subtype of non-Hodgkin lymphoma (NHL) associated with a high relapse risk without high-dose methotrexate-based induction and subsequent consolidation therapy.1 Commonly used consolidation strategies in patients with PCNSL include whole-brain radiotherapy, nonmyeloablative chemotherapy, and high-dose therapy with autologous hematopoietic cell transplant (AHCT), the latter of which abrogates the risk of chronic neurocognitive toxic effects associated with high-dose whole-brain radiotherapy.2-7 Extrapolating from experience with systemic lymphomas, early AHCT studies for PCNSL used carmustine/etoposide/cytarabine/melphalan (BEAM) conditioning with disappointing disease control and survival results.8-10 More recently, single-arm phase 2 studies demonstrated durable disease control and survival with central nervous system penetrant conditioning regimens, such as thiotepa/busulfan/cyclophosphamide (TBC) and thiotepa/carmustine (TT-BCNU).4,11-17Keywords
This publication has 37 references indexed in Scilit:
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)Journal of Clinical Oncology, 2013
- Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomasHaematologica, 2012
- Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin LymphomaTransplantation and Cellular Therapy, 2012
- SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards modelsComputer Methods and Programs in Biomedicine, 2011
- Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experienceBone Marrow Transplantation, 2010
- Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie CellulaireJournal of Clinical Oncology, 2008
- High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS groupBone Marrow Transplantation, 2006
- High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS LymphomaJournal of Clinical Oncology, 2006
- High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphomaBone Marrow Transplantation, 2003
- Pharmacology of agents used in bone marrow transplant conditioning regimensCritical Reviews in Oncology/Hematology, 1992